Epcoritamab Brings Hope to Relapsed Follicular Lymphoma Patients
In a promising development for patients battling relapsed or refractory follicular lymphoma (FL), new research has shown that combining epcoritamab (Epkinly) with the standard treatments lenalidomide (Revlimid) and rituximab (Rituxan) can drastically improve outcomes. This combination, often referred to as R2, led to a significant 79% reduction in the risk of disease progression or death, according to a recent study presented at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando, Florida.
The primary results of the phase 3 EPCORE FL-1 trial highlighted a striking difference in results, with an overall estimated survival rate of 95.8% for those receiving the epcoritamab combination, compared to 88.8% in the standard treatment group. This trial sought to address a critical gap in treatment efficiency for FL, a chronic condition that has historically been difficult to treat effectively.
Unmet Needs in FL Treatment
Dr. Lorenzo Falchi, leading the study at Memorial Sloan Kettering Cancer Center, noted the pressing need for improved therapies in this area. "Most patients with FL see responses decline significantly after initial treatments," he stated, emphasizing the limitations of the existing R2 regimen. The study suggests that while R2 has been a standard approach, its effectiveness often falters, especially for patients experiencing relapses.
Study Findings and Implications
A total of 488 participants were involved in the trial, with findings indicating strong objective response rates—95% for patients receiving epcoritamab plus R2, compared to 79% for R2 alone. The complete response rate further solidified the epcoritamab combination’s effectiveness, achieving 83% against R2's 50%. These results reflect an important potential shift in the treatment paradigm for FL, particularly for high-risk patients.
Dr. Joshua Brody, a hematologist oncologist who reviewed the trial's findings, claimed the results illustrate a “gigantic benefit” for the epcoritamab combination. He emphasized the importance of ongoing monitoring to confirm long-term advantages for patients. Given that the trial suggests the potential for deeper, more durable responses, healthcare providers may soon consider this combination as the new standard of care.
Looking Forward
With the FDA's approval of epcoritamab plus R2 in November 2025, both patients and oncologists have a reason to remain optimistic. Continued advancements in treatments like this are pivotal to improving patient survival rates and quality of life in those affected by relapsed or refractory follicular lymphoma. Further research will be crucial in ensuring that these promising results translate into lasting change for patients worldwide.
Add Row
Add
Write A Comment